SEC Form 4 · accession 0001055726-17-000003
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Bagarazzi
Officer — Chief Medical Officer
Period of report
Mar 5, 2017
Accepted (ET)
Mar 7, 2017 · 4:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 5, 2017 | M | 8,333 | — | A | 28,825 | D | |
| Common Stock | Mar 6, 2017 | F | 3,067 | $6.95 | D | 25,758 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Mar 5, 2017 | M | 8,333 | D | — | — | Common Stock | 8,333 | 8,333 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.